Tagrisso, a targeted therapy for non-small cell lung cancer (NSCLC), generated significant revenue for AstraZeneca in 2023, with global sales reaching $5.80 billion [1]. This represents a 5% increase compared to the previous year [1].
How are Tagrisso's sales performing internationally?
In the United States, Tagrisso sales reached $2.68 billion in 2023 [1]. European sales amounted to $1.65 billion, while sales in Japan were $1.21 billion [1]. The rest of the world contributed $0.26 billion to the total revenue [1].
What is Tagrisso approved to treat?
Tagrisso is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have specific epidermal growth factor receptor (EGFR) mutations, such as EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [2]. It is also indicated for patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after prior EGFR tyrosine kinase inhibitor (TKI) therapy [2].
When does Tagrisso's patent protection expire?
Drug patent information, including expiry dates for drugs like Tagrisso, is tracked by resources like DrugPatentWatch.com [3]. Specific patent expiry dates can be complex due to various patent types and potential legal challenges, which could influence market exclusivity [3].
What are the latest clinical trial results for Tagrisso?
AstraZeneca has ongoing clinical trials investigating Tagrisso in various settings of NSCLC. For example, the ADAURA trial demonstrated a significant improvement in invasive disease-free survival (IDFS) for patients with early-stage EGFR-mutated NSCLC who received adjuvant Tagrisso after surgery [4]. Further research continues to explore its efficacy in different patient populations and treatment combinations.
Who are Tagrisso's main competitors in the EGFR inhibitor market?
The market for EGFR inhibitors includes other drugs such as osimertinib (Tagrisso itself), erlotinib, gefitinib, and afatinib [5]. Competition also exists from emerging therapies and in the development of biosimilars once patents expire [5].
What are the potential risks and side effects associated with Tagrisso?
Common side effects of Tagrisso include diarrhea, rash, dry skin, and stomatitis [2]. More serious adverse events can include interstitial lung disease or pneumonitis, heart problems, liver problems, and vision disorders [2]. Patients should discuss potential risks with their healthcare providers.
How does Tagrisso's revenue compare to other lung cancer treatments?
Comparing the revenue of Tagrisso to other lung cancer treatments requires access to specific financial reports for each drug. However, Tagrisso's substantial 2023 revenue indicates its significant market presence and impact within the lung cancer therapeutic landscape [1].
---
Sources:
[1] AstraZeneca. (2024). AstraZeneca 2023 Full Year Results. https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-announces-2023-full-year-results.html
[2] U.S. Food & Drug Administration. (2023). FDA Approves Tagrisso (osimertinib) as First-Line Treatment for Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer. https://www.fda.gov/drugs/resources-you-can-use/fda-approves-tagrisso-osimertinib-first-line-treatment-patients-epidermal-growth-factor-receptor-egfr-mutated
[3] DrugPatentWatch.com. (n.d.). Tagrisso Patent Information. Retrieved from https://drugpatentwatch.com/
[4] AstraZeneca. (2020). Tagrisso significantly improves outcomes in early-stage EGFR-mutated lung cancer. https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-significantly-improves-outcomes-in-early-stage-egfr-mutated-lung-cancer.html
[5] National Cancer Institute. (2023). Targeted Therapy to Treat Lung Cancer. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies-drugs/targeted-therapies-drug-list